Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01899326 · ClinicalTrials.gov registry record · NA
Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
A NA study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01899326 is a NA study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT01899326, a NA study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This pilot clinical trial studied how well desipramine hydrochloride and filgrastim worked for stem cell mobilization in participants with multiple myeloma (MM) undergoing stem cell transplant. Giving colony-stimulating factors, such as filgrastim, and other drugs, such as desipramine hydrochloride, helps stem cells move from the participant's bone marrow to the blood so they can be collected and stored.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Filgrastim
- DRUG Desipramine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01899326
The ClinicalTrials.gov registry entry for NCT01899326 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01899326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01899326 about?
NCT01899326 is a clinical study titled "Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant". This pilot clinical trial studied how well desipramine hydrochloride and filgrastim worked for stem cell mobilization in participants with multiple myeloma (MM) undergoing stem cell transplant. Giving colony-stimulating factors, such as filgrastim, and other drugs, such as desipramine hydrochloride,...
What is the current status of trial NCT01899326?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2013-09. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01899326?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Filgrastim (BIOLOGICAL), Desipramine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01899326?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.